Isabelle Gorrillot, PhD is the Chief Innovation Officer at AI Therapeutics. Dr. Gorrillot is an experienced life science partnering executive with over 25 years of combined partnering experience in industry and academia, initiated in the drug delivery industry at ALZA Corp (acquired by J&J) and TheraTech (Acquired by Watson). She has a robust track record of success in all aspects of identifying, evaluating, and negotiating preclinical and clinical drug development and commercialization deals, as well as managing alliances, particularly in support of start-up and small biotech growth. An immunologist trained at the Pasteur Institute (France) Isabelle’s scientific expertise immune homeostasis in cancer, neurodegeneration, autoimmune diseases and inflammation, with a growing focus over the past 7 years on rare disease drug development. Isabelle has completed the USPTO bar exam preparatory course, several graduate courses in marketing, strategy and management at Stanford and UC Berkeley. Dr. Gorrillot gained peer recognition as a partnering expert at the university-industry interface and was a Trustee of the 3,000-member Licensing Executives Society USA-Canada. She is also a member of AUTM. Isabelle is an avid horseback rider (hunter/jumper) and former professional skier.